SGMT - Sagimet Biosciences Inc.
5.86
-0.010 -0.171%
Share volume: 252,135
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.87
-0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-15-2024 | 08-14-2024 | 11-14-2024 | 03-12-2025 | 05-08-2025 | 11-13-2025 | 03-11-2026 | |
| Assets | ||||||||
| Total Assets | 194.528 M | 189.020 M | 174.775 M | 160.259 M | 146.172 M | 128.401 M | 116.482 M | |
| Current Assets | 194.491 M | 166.751 M | 157.190 M | 152.774 M | 146.072 M | 119.480 M | 116.404 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 16.928 M | 70.414 M | 75.472 M | 75.410 M | 79.852 M | 84.197 M | 78.103 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 176.777 M | 95.959 M | 77.014 M | 75.840 M | 64.717 M | 32.496 M | 35.021 M | |
| Total Non-current Assets | 0.000 | 22.118 M | 17.471 M | 7.408 M | 0.000 | 8.806 M | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 37.000 K | 22.269 M | 17.585 M | 7.485 M | 100.000 K | 8.921 M | 78.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 194.528 M | 189.020 M | 174.775 M | 160.259 M | 146.172 M | 128.401 M | 116.482 M | |
| Total liabilities | 4.510 M | 5.728 M | 4.092 M | 4.454 M | 7.180 M | 9.146 M | 5.101 M | |
| Total current liabilities | 0.000 | 0.000 | 0.000 | 4.454 M | 0.000 | 9.146 M | 5.101 M | |
| Accounts Payable | 531.000 K | 1.994 M | 1.152 M | 1.425 M | 3.223 M | 4.243 M | 1.309 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 190.018 M | 183.292 M | 170.683 M | 155.805 M | 138.992 M | 119.255 M | 111.381 M | |
| Common stock | 446.384 M | 447.806 M | 449.352 M | 450.886 M | 452.358 M | 455.919 M | 457.610 M | |
| Retained earnings | -256.373 M | -264.491 M | -279.110 M | -295.311 M | -313.487 M | -336.781 M | -346.349 M |